Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edesa Biotech (EDSA) Total Non-Current Liabilities (2020 - 2022)

Edesa Biotech's Total Non-Current Liabilities history spans 5 years, with the latest figure at $5.7 million for Q2 2022.

  • For Q2 2022, Total Non-Current Liabilities rose 451.83% year-over-year to $5.7 million; the TTM value through Jun 2022 reached $5.7 million, up 451.83%, while the annual FY2021 figure was $1.5 million, 8.94% down from the prior year.
  • Total Non-Current Liabilities for Q2 2022 was $5.7 million at Edesa Biotech, up from $3.3 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $5.7 million in Q2 2022 and bottomed at $986250.0 in Q4 2020.
  • The 3-year median for Total Non-Current Liabilities is $1.6 million (2020), against an average of $2.4 million.
  • The largest YoY upside for Total Non-Current Liabilities was 451.83% in 2022 against a maximum downside of 28.75% in 2022.
  • A 3-year view of Total Non-Current Liabilities shows it stood at $986250.0 in 2020, then skyrocketed by 77.12% to $1.7 million in 2021, then surged by 223.86% to $5.7 million in 2022.
  • Per Business Quant, the three most recent readings for EDSA's Total Non-Current Liabilities are $5.7 million (Q2 2022), $3.3 million (Q1 2022), and $1.7 million (Q4 2021).